These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 11471772

  • 1. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.
    Jazwinska-Tarnawska E, Orzechowska-Juzwenko K, Niewinski P, Rzemislawska Z, Loboz-Grudzien K, Dmochowska-Perz M, Slawin J.
    Int J Clin Pharmacol Ther; 2001 Jul; 39(7):288-92. PubMed ID: 11471772
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M.
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L, O'Hara G, Lefebvre M, Lessard E, Gilbert M, Adedoyin A, Champagne J, Hamelin B, Turgeon J.
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [Abstract] [Full Text] [Related]

  • 7. Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.
    O'Hara GE, Philippon F, Gilbert M, Champagne J, Michaud V, Charbonneau L, Pruneau G, Hamelin BA, Geelen P, Turgeon J.
    J Clin Pharmacol; 2012 Feb; 52(2):171-9. PubMed ID: 21508180
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10.
    Doki K, Shirayama Y, Sekiguchi Y, Aonuma K, Kohda Y, Ieda M, Homma M.
    Pharmacogenomics; 2020 Dec; 21(18):1279-1288. PubMed ID: 33203295
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects.
    Cai WM, Chen B, Cai MH, Zhang YD.
    Zhongguo Yao Li Xue Bao; 1999 Aug; 20(8):720-4. PubMed ID: 10678105
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment.
    Boriani G, Martignani C, Biffi M, Capucci A, Branzi A.
    Drugs; 2002 Aug; 62(3):415-23. PubMed ID: 11827557
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: a randomized trial.
    Madonia S, De Simone M, Brai G, Gozzo D, Gristina A, Luciano L, Maisano S, Migliore G, Mineo R, Muzzo MP, Nicchi F, Randazzo A, Raspanti G, Rotolo G, Russo A, Sagona F, Schirosa M, Spinello M, Stancampiano R, Geraci E.
    Ital Heart J; 2000 Jul; 1(7):475-9. PubMed ID: 10933330
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Involvement of CYP2D6 activity in the N-oxidation of procainamide in man.
    Lessard E, Hamelin BA, Labbé L, O'Hara G, Bélanger PM, Turgeon J.
    Pharmacogenetics; 1999 Dec; 9(6):683-96. PubMed ID: 10634131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.